Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Cost and Utilization Outcomes After Exclusion of Dipeptidyl Peptidase-4 Inhibitors and Other Diabetes Drug Category Changes in a Self-Funded, State Employee Managed Care Plan.

King J, McAdam-Marx C, McCaleb R, Davis D, Bemberg GB, Johnson JT.

J Manag Care Spec Pharm. 2019 Jun;25(6):646-651. doi: 10.18553/jmcp.2019.25.6.646.

2.

Clinical Outcomes of Acid Suppressive Therapy Use in Hematology/Oncology Patients at an Academic Medical Center.

McCaleb RV, Gandhi AS, Clark SM, Clemmons AB.

Ann Pharmacother. 2016 Jul;50(7):541-7. doi: 10.1177/1060028016644469. Epub 2016 Apr 18.

PMID:
27091869
3.

New Inhaled Antimicrobial Formulations for Use in the Cystic Fibrosis Patient Population.

Campbell CT, McCaleb R, Manasco KB.

Ann Pharmacother. 2016 Feb;50(2):133-40. doi: 10.1177/1060028015621916. Epub 2015 Dec 20. Review.

PMID:
26692274
4.

Description of Respiratory Microbiology of Children With Long-Term Tracheostomies.

McCaleb R, Warren RH, Willis D, Maples HD, Bai S, O'Brien CE.

Respir Care. 2016 Apr;61(4):447-52. doi: 10.4187/respcare.03518. Epub 2015 Dec 15.

Supplemental Content

Loading ...
Support Center